Cancer-associated fibroblasts as architects of acquired immune-privileged-like niches in gastrointestinal cancers: lessons from ocular immune privilege and barrier biology

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Gastrointestinal cancers frequently develop immune exclusion and therapeutic resistance, yet these phenotypes are often described separately. Cancer-associated fibroblasts (CAFs) are key stromal architects of immune-excluded tumor microenvironments, and their heterogeneous states can evolve under chemotherapy, radiotherapy, immunotherapy, targeted therapy, and anti-angiogenic pressure. We propose that treatment-induced injury, inflammation, hypoxia, and repair signals reshape CAFs. These therapy-educated CAFs can construct acquired immune-privileged-like niches by integrating extracellular matrix remodeling, immunosuppressive secretomes, vascular-barrier remodeling, and spatial exclusion of cytotoxic immune cells. Ocular barrier biology offers a conceptual, not anatomical, analog for this spatial organization. In gastrointestinal tumors, these principles may be pathologically co-opted by myCAF-, iCAF-, and apCAF-like programs to restrict CD8+ T-cell and NK-cell access, recruit suppressive myeloid and regulatory populations, and impair drug delivery. This framework may guide spatial multiomics, digital pathology, radiomics, CAF-derived biomarkers, and spatially guided CAF reprogramming strategies. It also provides falsifiable questions for paired pre- and post-treatment sampling across gastrointestinal cancer types.